Title | Phenobarbital - Medication Template for NCLEX based medication |
---|---|
Author | ryann starcher |
Course | Medical Surgical Clinical |
Institution | San Joaquin Valley College |
Pages | 1 |
File Size | 57.3 KB |
File Type | |
Total Downloads | 99 |
Total Views | 160 |
Medication Template for NCLEX based medication...
ACTIVE LEARNING TEMPLATE:
Medication
Ryann Starcher STUDENT NAME _____________________________________ phenobarbital - Barbital, Luminal, Solfoton MEDICATION __________________________________________________________________________ REVIEW MODULE CHAPTER ___________ Barbiturate, Anticonvulsant, Sedative/hypnotic CATEGORY CLASS ______________________________________________________________________ PURPOSE OF MEDICATION
Expected Pharmacological Action Depresses sensory cortex, decreases motor activity and alters cerebellar function. Raises seizure threshold and inhibits transmission in the nervous system.
Therapeutic Use Sedation and anticonvulsant activity.
Complications Hangover, delirium, depression, drowsiness, excitation, lethargy, vertigo, respiratory depression, Laryngospasm, bronchospasm, hypotension, constipation, diarrhea, nausea, vomiting, photosensitivity, rashes, urticaria, phlebitis at IV site, arthralgia, myalgia, neuralgia, hypersensitivity reactions including angioedema and serum sickness, physical dependence, psychological dependence.
Medication Administration Status Epilepticus IV (Adults and Children >1 mo): 15–18 mg/kg in a single or divided dose, maximum loading dose 20 mg/kg. Maintenance Anticonvulsant IV, PO (Adults and Children >12 yr): 1–3 mg/kg/day as a single dose or 2 divided doses. Sedation PO, IM (Adults): 30–120 mg/day in 2–3 divided doses. Preoperative sedation—100–200 mg IM 1–1.5 hours before the procedure. Hypnotic PO, Subcut, IV, IM (Adults): 100–320 mg at bedtime. Hyperbilirubinemia PO (Adults): 90–180 mg/day in 2–3 divided doses.
Contraindications/Precautions Sensitivity to barbiturates, severe respiratory disease with dyspnea or obstruction, uncontrolled severe pain, manifest hepatic or familial history of porphyria; severe kidney disease; history of previous addiction to sedative hypnotics; uncontrolled pain; pregnancy (particularly early pregnancy) (category D), lactation; sustained release formulation for children...